DelveInsight’s, “Advanced Gastric Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Gastric Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Advanced Gastric Carcinoma Pipeline Report
- DelveInsight’s Advanced Gastric Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Gastric Carcinoma treatment.
- The leading companies working in the Advanced Gastric Carcinoma Market include Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers quibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
- Promising Advanced Gastric Carcinoma Pipeline Therapies in the various stages of development include pemetrexed, oxaliplatin, Catumaxomab, and others.
- May 2024:- Ono Pharmaceutical Co. Ltd- ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer. The purpose of study is to evaluate the efficacy and safety of ONO-4538 in patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) refractory to or intolerant of standard therapy.
- April 2024:- Astellas Pharma Inc.- The purpose of this study is to assess the safety, tolerability and antitumor activity of IMAB362 in Japanese subjects with locally advanced or metastatic Gastric or GEJ adenocarcinoma whose tumors have Claudin (CLDN) 18.2 Expression. This study will also assess pharmacokinetics and immunogenicity of IMAB362.
Request a sample and discover the recent advances in Advanced Gastric Carcinoma @ Advanced Gastric Carcinoma Pipeline Outlook Report
Advanced Gastric Carcinoma Overview
Advanced stomach cancer means that a cancer that began in the stomach has spread to at least one other part of the body, such as the liver or lungs. Stomach cancer can spread to the: liver, lungs, lymph nodes, and tissue lining the abdominal cavity (peritoneum). The symptoms of advanced stomach cancer depend on what part of the body the cancer has spread to. The most common symptoms of stomach cancer include: unexplained weight loss, feeling and being sick, stomach pain, difficulty swallowing, feeling tired. Advanced stage means your stomach cancer has spread. External radiotherapy can help to control your cancer and reduce symptoms.
Advanced Gastric Carcinoma treatments such as chemotherapy or radiotherapy or targeted drugs can sometimes help to reduce symptoms. Other treatments such as laser therapy or stents can treat a blockage in the stomach. Surgery can help relieve symptoms of advanced stomach cancer if your cancer is causing a blockage. Laser therapy uses hot beams of light to burn away cancer cells. This can help control symptoms of advanced stomach cancer.
Advanced Gastric Carcinoma Emerging Drugs
- Camrelizumab: Jiangsu Hengrui Medicine
Camrelizumab (formerly known as HR 301210, INCSHR 1210, SHR 1210) is a humanised high-affinity IgG4-kappa monoclonal antibody that targets the programmed cell death-1 receptor. Currently, it is in Phase III stage of clinical trial evaluation to treat advanced gastric or gastroesophageal junction adenocarcinoma.
- Pamiparib: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.
Learn more about Advanced Gastric Carcinoma in clinical trials @ Advanced Gastric Carcinoma Drugs
Advanced Gastric Carcinoma Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Advanced Gastric Carcinoma. The companies which have their Advanced Gastric Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine.
DelveInsight’s Advanced Gastric Carcinoma pipeline report covers around 50+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Discover more about Advanced Gastric Carcinoma in development @ Advanced Gastric Carcinoma Clinical Trials
Advanced Gastric Carcinoma Companies
Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers quibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
Advanced Gastric Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Advanced Gastric Carcinoma Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
To know more about Advanced Gastric Carcinoma, visit @ Advanced Gastric Carcinoma Segmentation
Scope of the Advanced Gastric Carcinoma Pipeline Report
- Coverage- Global
- Advanced Gastric Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Advanced Gastric Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Advanced Gastric Carcinoma Companies- Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers quibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
- Advanced Gastric Carcinoma Pipeline Therapies- pemetrexed, oxaliplatin, Catumaxomab, and others.
For further information on the Advanced Gastric Carcinoma Pipeline Therapeutics, reach out @ Advanced Gastric Carcinoma Products Development
Table of Content
- Introduction
- Executive Summary
- Advanced Gastric Carcinoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Advanced Gastric Carcinoma – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Camrelizumab: Jiangsu Hengrui Medicine
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Pamiparib: BeiGene
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Venadaparib: Idience
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Advanced Gastric Carcinoma Key Companies
- Advanced Gastric Carcinoma Key Products
- Advanced Gastric Carcinoma- Unmet Needs
- Advanced Gastric Carcinoma- Market Drivers and Barriers
- Advanced Gastric Carcinoma- Future Perspectives and Conclusion
- Advanced Gastric Carcinoma Analyst Views
- Advanced Gastric Carcinoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/